-

Caribou Biosciences Co-Founder Dr. Jennifer Doudna Awarded Nobel Prize in Chemistry

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, today announced that co-founder Jennifer Doudna, Ph.D., has been awarded the 2020 Nobel Prize in Chemistry. In awarding the prize to Dr. Doudna, the Swedish Academy cited her contributions to science for the co-development of CRISPR-Cas9, a genome editing breakthrough which has revolutionized biomedicine. The prize was also awarded to Emmanuelle Charpentier, Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University, Berlin, Germany.

“We could not be more excited to see Jennifer’s groundbreaking work and accomplishments recognized by the Nobel Prize,” said Rachel Haurwitz, Ph.D., President and CEO of Caribou Biosciences. “Jennifer’s discoveries and inventions in CRISPR-Cas9 genome editing have helped to revolutionize science and medicine with their enormous impact on health and society becoming clearer every day. Our team at Caribou and I are grateful every day to have Jennifer play a central role in the creation and advancement of our organization.”

Dr. Doudna is the Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences at the University of California, Berkeley where she is also an Investigator of the Howard Hughes Medical Institute and president and chair of the board of the Innovative Genomics Institute (IGI). She is also a faculty scientist at Lawrence Berkeley National Laboratory (Berkeley Lab), a senior investigator at the Gladstone Institutes, and an adjunct professor of cellular and molecular pharmacology at the University of California, San Francisco. Her work and discoveries have previously been recognized through the award of a Kavli Prize in Nanoscience, Japan Prize, BBVA Foundation Frontiers of Knowledge Award in Biomedicine, Canada Gairdner International Award, Princess of Asturias Award for Technical and Scientific Research, Massry Prize, Breakthrough Prize in Life Sciences, and the Alan T. Waterman Award.

The Nobel Prize is awarded for outstanding contributions in physics, chemistry, medicine or physiology, literature, peace, and economic sciences. The Nobel Prize in Chemistry is awarded by The Royal Swedish Academy of Sciences on recommendation from the Nobel Committee and represents one of the highest levels of achievement for researchers in the field.

About Caribou Biosciences, Inc.

Caribou is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR-Cas9 biology. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies and genome-edited natural killer (NK) cell therapies.

Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. Interested companies may contact Caribou at licensing@cariboubio.com.

For more information about Caribou, visit www.cariboubio.com and follow the Company @CaribouBio.

“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Contacts

Brooke Worthing
Ogilvy
brooke.worthing@ogilvy.com
248-763-4771

Caribou Biosciences, Inc.


Release Versions

Contacts

Brooke Worthing
Ogilvy
brooke.worthing@ogilvy.com
248-763-4771

More News From Caribou Biosciences, Inc.

Caribou Biosciences Announces Closing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share. In addition, Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less the under...

Caribou Biosciences Announces Pricing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Caribou. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Caribou, are ex...

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-label, multicenter ANTLER phase 1 clinical trial (NCT04637763) to evaluate the company’s lead product candidate, CB-010, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells that ha...
Back to Newsroom